Sanderling Ventures
Sanderling Ventures is an investment firm that works on building and funding new biomedical companies.
Business Model:
Revenue: $12.1M
Employees: 11-50
Rankings
Industries / Tags:
Detailed Sanderling Ventures Information
Geographic Data
Address: Suite 408
City: Montreal
State: quebec
Zip: H3A 2R7
Country: CA
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Facebook
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Sanderling Ventures is an investment company that specializes in seed and early-stage investments. It also participates in later-stage financings. The firm focuses on new biomedical market opportunities, including emerging technology in the areas such as biotechnology, life sciences, therapeutics and pharmaceuticals, drug delivery, medical devices, and instrumentation; imaging and diagnostics, medical informatics, healthcare information technology; and health care services. It seeks to invest in United States and Canada. Sanderling Ventures was founded by Robert McNeil in 1979 and is headquartered in Sam Mateo, California.
Contact Phone:
+16504012000
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 5/2007 | Naviscan | Series C | 15M |
| 3/2007 | Endocyte | Series C | 15M |
| 8/2010 | Taligen Therapeutics | Series B | 10M |
| 5/2020 | CalciMedica | Series C | 15M |
| 3/2021 | CalciMedica | Series D | 0 |
| 1/2009 | CalciMedica | Series C | 4M |
| 9/2002 | Trinity Biosystems | Series A | 1.5M |
| 7/2007 | Neomend | Series C | 6M |
| 1/2000 | Net32 | Venture Round | 12M |
| 4/2009 | Torax Medical | Series C | 15M |
| 7/2010 | TheraVida | Debt Financing | 3.6M |
| 6/2004 | Artielle ImmunoTherapeutics | Series A | 11M |
| 7/2008 | Gemin X Pharmaceuticals | Series C | 38M |
| 1/2006 | Xytis | Series B | 24.5M |
| 2/2007 | Chimerix | Series D | 23.1M |
| 11/2006 | Endocyte | Venture Round | 30M |
| 4/2005 | Actimis Pharmaceuticals | Series A | 6M |
| 6/2005 | Torax Medical | Series B | 10M |
| 11/2011 | Lineagen | Series B | 0 |
| 11/2008 | Pacira Pharmaceuticals | Series A | 85M |
| 1/2008 | Taligen Therapeutics | Series B | 65M |
| 6/2003 | CyThera | Venture Round | 2M |
| 8/2010 | Gemin X Pharmaceuticals | Series E | 8M |
| 4/2010 | Sotera Wireless | Series C | 10.8M |
| 1/2009 | Axikin Pharmaceuticals | Series A | 3M |
| 11/2014 | Liphorus Pharmaceuticals | Series A | 6.4M |
| 7/2007 | ViaCyte | Series C | 0 |
| 9/2003 | Chimerix | Series B | 3.1M |
| 8/2009 | Chimerix | Series E | 16.1M |
| 10/2010 | InfraReDx | Series D | 21M |
| 1/2010 | Neomend | Series D | 30M |
| 6/2008 | Asteres | Venture Round | 4M |
| 11/2009 | Trinity Biosystems | Debt Financing | 7.5M |
| 1/2003 | Torax Medical | Series A | 1.5M |
| 6/2021 | Glycomine | Series B | 0 |
| 8/2019 | Glycomine | Series B | 0 |
| 10/2001 | Cylene Pharmaceuticals | Series A | 3.5M |
| 1/2015 | Lineagen | Series C | 0 |
| 4/2001 | Genteric | Series B | 22M |
| 12/2013 | Lineagen | Series C | 0 |
| 9/2008 | Ista Pharmaceuticals | Debt Financing | 65M |
| 5/2000 | CardioNet | Series B | 6.9M |
| 9/2003 | Asteres | Series A | - |
| 6/2009 | NovoStent Corporation | Venture Round | 1.1M |
| 9/2012 | Torax Medical | Series D | 0 |
| 12/2008 | Lineagen | Series A | 5.8M |
| 4/2005 | InfraReDx | Series B | 2.8M |
| 8/2010 | Lineagen | Series A | 10.8M |
| 11/2016 | Glycomine | Series A | 0 |
| 4/2016 | DalCor Pharmaceuticals | Series B | 100M |
| 5/2003 | Endocyte | Series C | 12.6M |
| 7/2001 | Endocyte | Series B | 7.6M |
| 3/2004 | Zapaq | Series A | 6M |
| 8/2000 | BioSpace | Series B | 10M |
| 3/2020 | ViaCyte | Series D | 0 |
| 8/2005 | Sotera Wireless | Series A | 3M |
| 8/2008 | Altor BioScience | Series C | 15M |
| 9/2017 | SpecificiT Pharma | Seed Round | - |
| 4/2012 | TheraVida | Venture Round | 1M |
| 1/2007 | Cylene Pharmaceuticals | Series C | 44M |
| 4/2010 | Gemin X Pharmaceuticals | Series D | 16M |
| 11/2004 | Asteres | Series B | - |
| 11/2004 | Chimerix | Series C | 11M |
| 4/2014 | Sotera Wireless | Venture Round | 0 |
| 3/2008 | Sotera Wireless | Series B | 20.3M |
| 12/2011 | Sotera Wireless | Series D | 12.2M |
| 6/2008 | CoMentis | Series D | 0 |
| 2/2011 | Chimerix | Series F | 45M |
| 12/1997 | Genteric | Series A | 9M |
| 9/2006 | CoMentis | Series B | 50M |
| 1/2018 | Metavention | Series C | 0 |
| 11/2005 | Naviscan | Series B | 6.5M |
| 2/2013 | Sotera Wireless | Series D | 0 |
| 10/2001 | Aderis Pharmaceuticals | Series D | 0 |
| 2/2008 | CalciMedica | Series B | 5.5M |
| 1/2010 | Endocyte | Series C | 26M |
| 12/2009 | CalciMedica | Series C | 12M |
| 6/2008 | Actimis Pharmaceuticals | Venture Round | 9.6M |
| 8/2003 | InfraReDx | Series A | 4.4M |
| 1/2008 | InfraReDx | Series C | 15.6M |
| 11/2007 | Asteres | Series C | 4M |
| 4/2002 | Dynavax Technologies | Series D | 0 |
| 7/2006 | Trinity Biosystems | Series B | 21M |
| 10/2002 | Alteer | Venture Round | 0 |
| 11/2005 | Tomophase | Series A | 4.5M |
| 7/2016 | Torax Medical | Series E | 0 |
| 7/2013 | ViaCyte | Series C | 10.6M |
| 3/2004 | CardioNet | Series D | 0 |
| 7/2017 | PreciThera | Series A | 28.7M |
| 1/2003 | CardioNet | Series C | 0 |
| 5/2006 | ViaCyte | Venture Round | 0 |
| 8/2005 | Alteer | Venture Round | 16.5M |
| 2/2004 | Kadmus Pharmaceuticals | Series A | 0 |
| 11/2018 | ViaCyte | Series D | 0 |
| 6/2021 | Glycomine | Series B | 0 |
| 3/2021 | CalciMedica | Series D | 0 |
| 5/2020 | CalciMedica | Series C | 0 |
| 3/2020 | ViaCyte | Series D | 0 |
| 8/2019 | Glycomine | Series B | 0 |
| 11/2018 | ViaCyte | Series D | 0 |
| 1/2018 | Metavention | Series C | 0 |
| 9/2017 | SpecificiT Pharma | Seed Round | - |
| 7/2017 | PreciThera | Series A | 0 |
| 11/2016 | Glycomine | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
